WO2006120501A1 - Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use - Google Patents
Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use Download PDFInfo
- Publication number
- WO2006120501A1 WO2006120501A1 PCT/IB2005/002357 IB2005002357W WO2006120501A1 WO 2006120501 A1 WO2006120501 A1 WO 2006120501A1 IB 2005002357 W IB2005002357 W IB 2005002357W WO 2006120501 A1 WO2006120501 A1 WO 2006120501A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disorders
- once
- eslicarbazepine
- eslicarbazepine acetate
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Definitions
- the present disclosure relates to a pharmaceutical composition and a treatment method using eslicarbazepine acetate.
- Eslicarbazepine acetate (S)-(-)-10-acetoxy-10,11 -dihydro-5H- dibenz/b,f/azepine-5-carboxamide (“BIA 2-093")
- BIOA 2-093 Eslicarbazepine acetate, (S)-(-)-10-acetoxy-10,11 -dihydro-5H- dibenz/b,f/azepine-5-carboxamide
- eslicarbazepine acetate is believed to avoid the production of certain toxic metabolites (such as, for example, epoxides) and to avoid the unnecessary production of enantiomers or diastereoisomers of metabolites and conjugates, without losing pharmacological activity.
- toxic metabolites such as, for example, epoxides
- eslicarbazepine acetate is believed to avoid the production of certain toxic metabolites (such as, for example, epoxides) and to avoid the unnecessary production of enantiomers or diastereoisomers of metabolites and conjugates, without losing pharmacological activity.
- eslicarbazepine acetate is believed to be a voltage-gated sodium channel (VGSC) blocker that competitively interacts with site 2 of the inactivated state of the sodium channel.
- VGSC voltage-gated sodium channel
- the affinity for this state of the channel is similar to that of carbamazepine, while the affinity for the resting state of the channel is about 3-fold lower than that of carbamazepine.
- This profile may suggest an enhanced inhibitory selectivity of eslicarbazepine acetate for rapidly firing neurons over those displaying normal activity.
- the inventors performed entry-into-man studies in healthy subjects, the results of which they described in the Almeida I and Almeida Il articles, both of which are hereby incorporated by reference.
- the healthy subjects received a single oral dose of eslicarbazepine acetate wherein the dose ranged from 20 mg to 1200 mg (see Almeida II), and multiple daily-doses of eslicarbazepine acetate ranging from 200 mg twice- daily to 1200 mg once-daily (see Almeida I).
- U.S. Patent No. 6,296,873 discloses a sustained release delivery system for carbamazepine, which has a half-life ranging from 25 hours to 85 hours. To avoid adverse effects, U.S. Patent No. 6,296,873 teaches that the carbamazepine should be administered in tablet form up to two or more times daily to slowly release the compound to maintain concentration levels between 4-12 ⁇ g/mL. Such a delivery system requires a form that is capable of delivering the compound over an extended period of time, such as a tablet form.
- the inventors have unexpectedly discovered an enhanced efficacy of eslicarbazepine acetate in the treatment of various conditions, such as, for example, the treatment of epilepsy, using once-daily administration compared to twice-daily administration.
- the inventors have also unexpectedly discovered an enhanced exposure to eslicarbazepine after once-daily administration of eslicarbazepine acetate versus the twice-daily regimen in humans.
- Once-daily administration of eslicarbazepine acetate surprisingly provides an increase of exposure to eslicarbazepine than the same drug dosage divided into twice-daily doses.
- Figure 1 Percentage reduction in seizure number in each dose period versus baseline (400 mg once-daily versus twice-daily and placebo; 800 mg once-daily versus twice-daily and placebo; 1200 mg once-daily versus twice-daily and placebo).
- Figure 2 Mean (95% Cl) trough plasma concentrations ( ⁇ g/ml_) of BIA 2-005 following a daily dose of 400 mg, 800 mg and 1200 mg of BIA-2- 093 administered once-daily (o.d.) or twice-daily (b.i.d.).
- One aspect of the present disclosure relates to a method for treating at least one disease or condition in a patient in need thereof by administering a pharmaceutical composition comprising eslicarbazepine acetate in a pharmacologically effective amount.
- a pharmaceutical composition comprising eslicarbazepine acetate is administered in a once-daily dosing regimen.
- the pharmaceutical composition is administered in a dosage intended to maximize the total exposure to eslicarbazepine, as measured by the rate of exposure
- the at least one disease or condition treated may be chosen from, for example, epilepsy, central and peripheric nervous system disorders, affective disorders, schizoaffective disorders, bipolar disorders, attention disorders, anxiety disorders, neuropathic pain and neurophratic pain-related disorders, sensorimotor disorders, vestibular disorders, and nervous function alterations in degenerative and post-ischemic diseases.
- affective disorders include depression, premenstrual dysphoric disorder, post-partum depression, post-menopausal depression, anorexia nervosa, bulimia nervosa, and neurodegeneration- related depressive symptoms.
- the methods disclosed in the present disclosure may be used to treat schizoaffective disorders such as, for example, schizodepressive syndromes, schizophrenia, extreme psychotic states, schizomanic syndromes, dysphoric and aggressive behavior, episodic dyscontrol or intermittent explosive disorder, and borderline personality disorder.
- schizoaffective disorders such as, for example, schizodepressive syndromes, schizophrenia, extreme psychotic states, schizomanic syndromes, dysphoric and aggressive behavior, episodic dyscontrol or intermittent explosive disorder, and borderline personality disorder.
- Bipolar disorders that may be treated according to the methods of the present disclosure include, for example, bipolar disorder and unstable bipolar disorder with rapid fluctuations (rapid cyclers), manic-depressive disorders, acute mania, mood episodes, and manic and hypomanic episodes
- attention disorders include attention deficit hyperactivity disorders and other attention disorders, such as, for example, autism.
- Anxiety disorders may include conditions such as, for example, social anxiety disorders, post traumatic stress disorder, panic, obsessive- compulsive disorder, alcoholism, drug withdrawal syndromes, and cravings.
- neuropathic pain and neurophratic pain-related disorders that may be treated according to the methods of the present disclosure include, by way of example, neuropathic pain and associated hyperalgesia, including trigeminal, herpetic, post-herpetic and tabetic neuralgia, diabetic neuropathic pain, migraines, tension-type headaches, causalgia, and deafferentation syndromes such as, for example, brachial plexus avulsion.
- sensorimotor disorders include Restless legs syndrome, spasticity, hemifacial spasm, nocturnal paroxysmal dystonia, brain ischemia associated motor and sensitive deficits, Parkinson's disease and parkinsonian disorders, antipsychotic-induced motor deficits, tardive dyskinesia, episodic nocturnal wandering, and myotonia.
- Exemplary vestibular disorders include Tinnitus or other inner ear/cochlear excitability related diseases, such as, for example, neuronal loss, hearing loss, sudden deafness, vertigo, and Meniere's disease.
- the at least one disease or condition may be chosen from epilepsy, bipolar disorder, and trigeminal neuralgia.
- the disease may be refractory partial epilepsy.
- Another aspect of the present disclosure relates to a pharmaceutical composition
- a pharmaceutical composition comprising eslicarbazepine acetate and at least one pharmaceutical excipient, at least one auxiliary substance, at least one carrier material, or combinations thereof.
- a further aspect of the present disclosure relates to a method of preparing a pharmaceutical composition
- a method of preparing a pharmaceutical composition comprising combining eslicarbazepine acetate with at least one excipient, at least one auxiliary substance, at least one carrier material, or combinations thereof.
- Suitable excipients, carrier materials, and other auxiliary substances which would be useful in the present invention are known to those skilled in the art, and would be readily determined. Methods for preparing pharmaceutical compositions are also known to those skilled in the art.
- the pharmaceutical composition may be in tablet form and may comprise at least one excipient, auxiliary substance, and/or carrier material.
- the at least one excipient, auxiliary substance, and/or carrier material may be chosen from, for example, povidone, croscarmellose sodium, magnesium stearate, saccharin sodium, dibasic calcium phosphate dihydrate, sodium lauryl sulphate, flavorings, and combinations thereof.
- Exemplary tablets may be formed using granulation liquids, such as, for example, purified water and ethanol.
- the pharmaceutical composition may be in oral suspension form and may comprise at least one excipient, auxiliary substance, and/or carrier material.
- the at least one excipient, auxiliary substance, and/or carrier material may be chosen from, for example, xantham gum, macrogol stearate (such as, for example, Myrj 59 P, produced by UNIQEMA), methylparaben, propylparaben, saccharin sodium, sorbitol, buffers, flavorings, and combinations thereof.
- Another aspect of the present disclosure relates to a method for reducing or decreasing the number, duration, or frequency of epileptic seizures in a patient by administering to the patient a dose of a pharmaceutical composition comprising eslicarbazepine acetate in a pharmacologically effective amount.
- the method for reducing epileptic seizures in patients comprises administering a once-daily dose of the pharmaceutical composition comprising a pharmacologically effective amount of eslicarbazepine acetate.
- the present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient by administering to the patient a pharmaceutical composition comprising eslicarbazepine acetate in an amount effective to increase the plasma concentration of eslicarbazepine over the dosage interval.
- the exposure to eslicarbazepine may be increased by delivering the pharmaceutical composition in a manner that minimizes the number of daily doses.
- the method for increasing the exposure to eslicarbazepine in the patient comprises administering to a patient a once-daily dose of a pharmaceutical composition comprising an amount of eslicarbazepine acetate effective to increase the plasma concentration of eslicarbazepine over the dosage interval.
- the active ingredient of the pharmaceutical composition may consist essentially of eslicarbazepine acetate.
- eslicarbazepine acetate may be administered to a patient in an amount resulting in a maximum plasma concentration (C ma ⁇ ) of eslicarbzepine greater than about 7,400 ng/mL. In other exemplary embodiments, eslicarbazepine acetate may be administered to a patient in an amount resulting in a C max of eslicarbazepine greater than about 12,000 ng/mL or greater than about 16,100 ng/mL.
- eslicarbazepine acetate may be administered to a patient in an amount resulting in a C max of eslicarbazepine greater than about 22,700 ng/mL, such as greater than about 36,500 ng/ml, greater than about 45,200 ng/mL, or more.
- eslicarbazepine acetate may be administered to a patient in an amount resulting in a maximum plasma concentration (C max ) of eslicarbzepine up to about 58,800 ng/mL or up to about 67,800 ng/mL. In a further exemplary embodiment, eslicarbazepine acetate may be administered to a patient in an amount resulting in a maximum plasma concentration (C max ) of eslicarbzepine up to about 885,000 ng/mL or up to about 1 ,000,000 ng/mL.
- C max maximum plasma concentration
- a once-daily dose of about 400 mg may be administered to a patient resulting in a maximum plasma concentration (C ma ⁇ ) of eslicarbazepine greater than about 7,400 ng/mL.
- a once-daily dose of about 800 mg or about 1200 mg may be administered to a patient resulting in a C max of eslicarbazepine greater than about 16,100 ng/mL or greater than about 22,700 ng/mL, respectively.
- eslicarbazepine acetate may be administered in a once-daily dose greater than about 1200 mg, such as about 1800 mg or about 2400 mg, to result in a Cmax of eslicarbazepine greater than about 36,500 ng/mL, about 45,200 ng/mL, respectively.
- eslicarbazepine acetate may be administered to a patient in an amount resulting in an area under the concentration curve (which corresponds to the extent of systemic
- acetate may be administered to a patient in an amount resulting in an AUCo- ⁇
- eslicarbazepine greater than about 240,000 ng-h/mL or greater than about 375,000 ng-h/mL, respectively.
- eslicarbazepine greater than about 595,000 ng-h/mL, greater than about 790,000 ng-h/mL, or more.
- a once-daily dose of about 400 mg may be administered resulting in an area under the concentration curve (which corresponds to the extent of systemic exposure) over the dosing interval
- AUC-o-t of eslicarbazepine greater than about 110,000 ng-h/mL.
- mg may be administered resulting in an AUC 0-T of eslicarbazepine greater than
- eslicarbazepine acetate may be administered in a once- daily dose greater than about 1200 mg, such as about 1800 mg, about 2400
- a once- daily dose may be administered in a dosage comprising at least about 400 mg of eslicarbazepine acetate.
- a once-daily dose may be administered in a dosage comprising an amount of eslicarbazepine acetate ranging from about 800 mg to about 1200 mg.
- a once-daily dose may be administered in a dosage comprising an amount of eslicarbazepine greater than about 1200 mg, such as about 1800 mg, about 2400 mg, or more.
- composition comprising eslicarbazepine acetate may optionally be administered by any route known to those skilled in the art, and may be in a form chosen from, for example, tablets or oral suspensions, or other forms.
- a "method of treating” as described herein refers to administering to a patient the compound described in any amount effective to reduce the effects of, counteract, or eliminate the disease or condition being treated, or the symptoms thereof.
- a "method for increasing the exposure to eslicarbazepine in a patient” as described herein refers to administering to a patient the compound described in any amount effective to increase the plasma concentration of eslicarbazepine in the patient over the dosage interval. This may, for example, be an increase due to once-daily dosing relative to twice-daily dosing.
- Reducing epileptic seizures in a patient refers to any decrease in the number, duration, or frequency of epileptic seizures in a patient relative to the number, duration, or frequency of epileptic seizures experienced by the patient without treatment.
- a "pharmacologically effective amount" of eslicarbazepine acetate in a pharmaceutical composition as described herein refers to any amount sufficient to have the desired pharmacological activity.
- AEDs antiepileptic drugs
- This human pharmacology trial was a study to investigate the steady-state pharmacokinetics of once-daily and twice-daily regimens of eslicarbazepine acetate in healthy subjects.
- the study was a single center, open-label, randomized, two-way crossover study in 12 healthy volunteers (6 males and 6 females) that consisted of two 8-day treatment periods separated by a washout period of 10-15 days.
- the volunteers received either a daily oral dose of eslicarbazepine acetate 900 mg once-daily (o.d.) or eslicarbazepine acetate 450 mg twice-daily (b.i.d.). Tablets with a strength of 450 mg of eslicarbazepine acetate, manufactured by BIAL (S. Mamede do Coronado, Portugal) in accordance with Good Manufacturing Practice, were used.
- Phase A pre-dose, and Vz, 1 , 1 1 /2, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours post-dose
- Phase B day 5 to day 11 (inclusive): before the daily dose (for "trough” concentrations assay); day 12: pre-dose, and V 2 , 1 , VA, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose.
- Blood samples were drawn either by direct venipuncture or via an intravenous catheter into lithium heparin tubes and centrifuged at approximately 1500 g for 10 minutes at 4 S C. The resulting plasma was separated into 2 equal aliquots of 1 ml_ and stored at -20 s C until required for analysis.
- Plasma concentrations of eslicarbazepine acetate, eslicarbazepine, and R-licarbazepine were determined using isocratic liquid chromatography (LC) with single quadrupole mass spectrometry detection (MS).
- the LC-MS system used in the analysis consisted of a Perkin Elmer series 200 micro pump, a Perkin Elmer series 200 autosampler, and a Perkin Elmer/Sciex API 150EX single quadrupole mass spectrometer fitted
- LichroCART 250-4 ChiraDex column ( ⁇ -cyclodextrin, 5 ⁇ m), a LichroCART 4-4
- MS detector was operated in positive ion mode with mass transitions for BIA 2-093, eslicarbazepine, R-licarbazepine, and the internal standard of 319.16 amu (200 ms), 277.08 amu (200 ms), 277.08 amu (200 ms) and
- the internal standard, 10,11-dihydrocarbamazepine was supplied by Sigma- Aldrich (St. Louis, MO).
- the pharmacokinetic parameters were derived from non- compartmental analysis using WinNonlin (Version 4.0, Pharsight Corporation, Mountain View, California). The following parameters were derived, where appropriate, from the individual plasma concentration-time profiles: maximum observed plasma concentration (C ma ⁇ ); time of occurrence of C ma ⁇ (W); area under the plasma concentration versus time curve (AUC) from time zero to the last sampling time (t) at which concentrations were at or above the limit of quantification (AUC 0- t), calculated by the linear trapezoidal rule; AUC over the
- AUC ⁇ dosing interval
- This human pharmacology trial was a study to determine the pharmacokinetics of eslicarbazepine acetate following single and repeated doses. The study integrated the results of three double-blind, randomized, placebo-controlled trials. To measure the pharmacokinetics of eslicarbazepine acetate following single doses, oral single doses of eslicarbazepine acetate ranging from 20 mg to 2400 mg were administered to healthy young male subjects (6 subjects per dose).
- valproic acid 68.0%, 60.9% and 66.0% of patients in the once-daily, twice- daily, and placebo groups, respectively
- topiramate 36.0%, 34.8%, and 21.3%, respectively
- lamotrigine 30.0%, 28.3%, and 31.9%, respectively.
- IA simple partial, IB complex partial, and IC partial evolving to secondarily generalized were present in, respectively, 34.0%, 72.0%, and 80.0%, in the once-daily group; 37.0%, 71.7%, and 80.4%, in the twice-daily group; and 27.7%, 80.9%, and 72.3%, in the placebo group.
- the mean of total number of seizures per month prior to the study was 14.1 , 13.6, and 11.8, in the once-daily, twice-daily, and placebo groups, respectively.
- Secondary endpoints include the reduction in total seizure frequency, proportion of seizure-free patients, distribution of responders, comparison of once and twice daily regimens, and investigator's and patient's global evaluation.
- BIA 2-005 and concomitant AEDs were collected at all visits but V5 (post-study visit).
- the objective was to characterize the influence of eslicarbazepine acetate on the pharmacokinetic behavior of the concomitant AEDs (e.g., phenytoin, valproate, primidone, phenobarbital, lamotrigine, gabapentin, topiramate, and clonazepam).
- the mean trough plasma concentrations of BIA 2-005 are displayed in Table 1. As shown in Figure 2, no significant differences in the BIA 2-005 trough (pre-dose) values between the once-daily and twice-daily groups were found.
- Table 1 Trough plasma concentrations of BIA 2-005 following oral administration of eslicarbazepine acetate once-daily (o.d.) and twice-daily (b.i.d)
- the mean trough serum concentrations of valproate were not significantly changed by concomitant administration of eslicarbazepine acetate once-daily (7.0%; 95% IC: -7.6, 36.2) or twice-daily (6.3%; 95% IC: -7.5, 20.1).
- a significant increase in the serum levels of valproate was noticed (25.4%; 95% IC: 5.1 , 45.8).
- With respect to lamotrigine its serum levels were not significantly changed when eslicarbazepine acetate once-daily (-10.0%; 95% IC: -46.2, 26.2) or placebo (12.6%; 95% IC: -12.6, 37.8) were added to therapy.
- Eslicarbazepine acetate was shown to be extensively metabolized to eslicarbazepine and, in a minor extent, to R-licarbazepine.
- the steady-state of eslicarbazepine plasma concentrations was attained at 4 to 5 days of administration in both groups.
- mean C max of eslicarbazepine and R-licarbazepine was, respectively, 22,210 ng/mL and 674 ng/mL and occurred at (median W) 2.45 hours and 9.42 hours post-dose, respectively.
- Mean AUCo-tOf eslicarbazepine and R-licarbazepine was 381 ,601 ng-h/mL and 19,600 ng-h/mL, respectively.
- mean C 013x of eslicarbazepine and R-licarbazepine was 16,667 ng/mL and 718 ng/mL, respectively, and occurred (median t max ) at 2.09 hours and 6.40 hours post-dose, respectively.
- Mean AUC 0- t ⁇ f eslicarbazepine and R-licarbazepine was 283,014 ng-h/mL and 19,661 ng-h/mL, respectively.
- eslicarbazepine was shown to be the major metabolite, representing approximately 95% and 96% of total systemic drug exposure (as assessed by AUCo- 24 ) in once-daily and twice-daily subjects, respectively.
- Tables 2 and 3 depict the eslicarbazepine and R-licarbazepine pharmacokinetic parameters in the once-daily and twice- daily groups following the last dose of eslicarbazepine acetate.
- the total exposure of healthy volunteers to eslicarbazepine in the once-daily group was unexpectedly at least 26% higher than in the twice-daily group.
- Table 2 Mean pharmacokinetic parameters of eslicarbazepine and R-licarbazepine following a multiple oral dose of 900 mg eslicarbazepine acetate once-daily.
- Table 3 Mean pharmacokinetic parameters of eslicarbazepine and R-licarbazepine following a multiple oral dose of 900 mg eslicarbazepine acetate twice-daily.
- mean Cmax of eslicarbazepine ranged from 8,800 ng/ML-(16.0% coefficient of variation, CV) for 400 mg doses of eslicarbazepine acetate to 56,500 ng/ML-(20.0% CV) for 2400 mg doses of eslicarbazepine acetate.
- the maximum plasma concentration for all dosages occurred (median t ma ⁇ ) at 2 hours to 3.5 hours.
- Eslicarbazepine acetate was shown to be extensively metabolized to eslicarbazepine and, in a minor extent, to R-licarbazepine.
- Eslicarbazepine represented between 95% and 98% of total systemic drug exposure (as assessed by AUC 0 - ⁇ , i.e., AUC over the dosing interval) and,
- Plasma concentrations of parent drug were systematically found to be below the limit of quantification. With multiple-dosing, steady-state plasma concentrations were attained at 4 to 5 days of administration in both groups, consistent with an effective half-life on the order of about 20-24 hours.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0520258-2A BRPI0520258A2 (en) | 2005-05-06 | 2005-05-06 | use of a pharmaceutical composition, method for preparing a pharmaceutical composition, and use of an effective amount of eslicarbazepine acetate |
AU2005331690A AU2005331690C1 (en) | 2005-05-06 | 2005-05-06 | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
MX2014010152A MX366496B (en) | 2005-05-06 | 2005-05-06 | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use. |
CA2607427A CA2607427C (en) | 2005-05-06 | 2005-05-06 | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
PCT/IB2005/002357 WO2006120501A1 (en) | 2005-05-06 | 2005-05-06 | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
MX2007013882A MX2007013882A (en) | 2005-05-06 | 2005-05-06 | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use. |
ARP060101835A AR055939A1 (en) | 2005-05-06 | 2006-05-05 | METHODS TO PREPARE PHARMACEUTICAL COMPOSITIONS THAT INCLUDE ACETATO DE ESLICARBAZEPINA AND METHODS OF USE |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2005/002357 WO2006120501A1 (en) | 2005-05-06 | 2005-05-06 | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006120501A1 true WO2006120501A1 (en) | 2006-11-16 |
Family
ID=35335795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2005/002357 WO2006120501A1 (en) | 2005-05-06 | 2005-05-06 | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
Country Status (5)
Country | Link |
---|---|
AU (1) | AU2005331690C1 (en) |
BR (1) | BRPI0520258A2 (en) |
CA (1) | CA2607427C (en) |
MX (2) | MX366496B (en) |
WO (1) | WO2006120501A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007094694A1 (en) * | 2006-02-14 | 2007-08-23 | Bial Portela & C.A., S.A. | Use of 5h-dibenz/b,f/azepine-5-carboxamide derivatives in the treatment of neuropathic pain and neurological disorders |
WO2008088233A1 (en) * | 2007-01-15 | 2008-07-24 | Bial-Portela & Ca., S.A. | Therapeutical uses of eslicarbazepine |
WO2010015029A1 (en) * | 2008-08-06 | 2010-02-11 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating psychiatric disorders |
EP2380574A1 (en) * | 2005-05-06 | 2011-10-26 | Bial-Portela & CA, S.A. | Eslicarbazepine acetate and methods of use |
WO2012091593A1 (en) * | 2010-12-31 | 2012-07-05 | Bial - Portela & Ca., S.A. | Granulates comprising eslicarbazepine acetate |
US8372431B2 (en) | 2007-10-26 | 2013-02-12 | Bial-Portela & C.A., S.A. | Pharmaceutical composition comprising licarbazepine acetate |
WO2013032351A1 (en) * | 2011-08-26 | 2013-03-07 | BIAL - PORTELA & Cª, S.A. | Treatments involving eslicarbazepine acetate or eslicarbazepine |
WO2014163518A1 (en) * | 2013-04-04 | 2014-10-09 | BIAL - PORTELA & Cª, S.A. | Treatments involving eslicarbazepine or eslicarbazepine acetate |
US8957099B2 (en) | 2007-02-07 | 2015-02-17 | Gosforth Centre (Holdings) Pty Ltd. | Treatment of ADHD |
US9855277B2 (en) | 2009-07-27 | 2018-01-02 | Bial—Portela & Ca, S.A. | Use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives for treating fibromyalgia |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0751129A1 (en) * | 1995-06-30 | 1997-01-02 | Portela & Ca., S.A. | Substituted dihydrodibenzo/b, f/azepines, method for their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them |
WO2004087168A1 (en) * | 2003-04-02 | 2004-10-14 | Novartis Ag | Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
-
2005
- 2005-05-06 CA CA2607427A patent/CA2607427C/en active Active
- 2005-05-06 BR BRPI0520258-2A patent/BRPI0520258A2/en not_active Application Discontinuation
- 2005-05-06 MX MX2014010152A patent/MX366496B/en unknown
- 2005-05-06 AU AU2005331690A patent/AU2005331690C1/en active Active
- 2005-05-06 MX MX2007013882A patent/MX2007013882A/en active IP Right Grant
- 2005-05-06 WO PCT/IB2005/002357 patent/WO2006120501A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0751129A1 (en) * | 1995-06-30 | 1997-01-02 | Portela & Ca., S.A. | Substituted dihydrodibenzo/b, f/azepines, method for their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them |
WO2004087168A1 (en) * | 2003-04-02 | 2004-10-14 | Novartis Ag | Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2380574A1 (en) * | 2005-05-06 | 2011-10-26 | Bial-Portela & CA, S.A. | Eslicarbazepine acetate and methods of use |
WO2007094694A1 (en) * | 2006-02-14 | 2007-08-23 | Bial Portela & C.A., S.A. | Use of 5h-dibenz/b,f/azepine-5-carboxamide derivatives in the treatment of neuropathic pain and neurological disorders |
RU2488397C2 (en) * | 2007-01-15 | 2013-07-27 | БИАЛ-ПОРТЕЛА энд КА., С.А. | Therapeutic use of eslicarbazepine |
EP3222323A1 (en) * | 2007-01-15 | 2017-09-27 | BIAL - Portela & Ca., S.A. | Therapeutical uses of eslicarbazepine |
WO2008088233A1 (en) * | 2007-01-15 | 2008-07-24 | Bial-Portela & Ca., S.A. | Therapeutical uses of eslicarbazepine |
JP2010515727A (en) * | 2007-01-15 | 2010-05-13 | バイアル−ポルテラ アンド シーエー,エス.エー. | Therapeutic use of eslicarbazepine |
US9763954B2 (en) | 2007-01-15 | 2017-09-19 | Bial—Portela & Ca, S.A. | Therapeutical uses of eslicarbazepine |
EP2121138B1 (en) | 2007-01-15 | 2016-09-14 | BIAL - Portela & Ca., S.A. | Therapeutical uses of eslicarbazepine |
US8957099B2 (en) | 2007-02-07 | 2015-02-17 | Gosforth Centre (Holdings) Pty Ltd. | Treatment of ADHD |
US9649297B2 (en) | 2007-02-07 | 2017-05-16 | Gosforth Centre (Holdings) Pty Ltd. | Treatment of ADHD |
US8372431B2 (en) | 2007-10-26 | 2013-02-12 | Bial-Portela & C.A., S.A. | Pharmaceutical composition comprising licarbazepine acetate |
US9566244B2 (en) | 2007-10-26 | 2017-02-14 | Bial-Portele & Ca, S.A. | Pharmaceutical composition comprising licarbazepine acetate |
US10912781B2 (en) | 2007-10-26 | 2021-02-09 | Bial-Portela & C.A., S.A. | Pharmaceutical composition comprising licarbazepine acetate |
US10028971B2 (en) | 2008-08-06 | 2018-07-24 | Gosforth Centre (Holdings) Pty Ltd. | Compositions and methods for treating psychiatric disorders |
WO2010015029A1 (en) * | 2008-08-06 | 2010-02-11 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating psychiatric disorders |
US9855277B2 (en) | 2009-07-27 | 2018-01-02 | Bial—Portela & Ca, S.A. | Use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives for treating fibromyalgia |
WO2012091593A1 (en) * | 2010-12-31 | 2012-07-05 | Bial - Portela & Ca., S.A. | Granulates comprising eslicarbazepine acetate |
US9750747B2 (en) | 2011-08-26 | 2017-09-05 | Bail-Portela & Ca, S.A. | Treatments involving eslicarbazepine acetate or eslicarbazepine |
WO2013032351A1 (en) * | 2011-08-26 | 2013-03-07 | BIAL - PORTELA & Cª, S.A. | Treatments involving eslicarbazepine acetate or eslicarbazepine |
US20160051560A1 (en) * | 2013-04-04 | 2016-02-25 | Bial- Portela & Ca, S.A. | Treatments involving eslicarbazepine or eslicarbazepine acetate |
WO2014163518A1 (en) * | 2013-04-04 | 2014-10-09 | BIAL - PORTELA & Cª, S.A. | Treatments involving eslicarbazepine or eslicarbazepine acetate |
Also Published As
Publication number | Publication date |
---|---|
CA2607427C (en) | 2015-11-24 |
BRPI0520258A2 (en) | 2009-09-15 |
AU2005331690A1 (en) | 2006-11-16 |
CA2607427A1 (en) | 2006-11-16 |
MX366496B (en) | 2019-07-11 |
AU2005331690C1 (en) | 2013-01-17 |
MX2007013882A (en) | 2008-01-28 |
AU2005331690B2 (en) | 2012-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11364247B2 (en) | Methods of treatment of partial onset seizures using eslicarbazepine acetate | |
EP2384755A1 (en) | Eslicarbazepine acetate and methods of use | |
CA2607427C (en) | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use | |
Falcão et al. | Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2‐093), a new voltage‐gated sodium channel blocker | |
KR20050116368A (en) | Menthol solutions of drugs | |
US20080161404A1 (en) | Bicalutamide for Delivering Increasing Steady State Plasma Levels | |
JP2016047838A (en) | Eslicarbazepine acetate and methods of use | |
JP2013237676A (en) | Eslicarbazepine acetate and use method | |
RU2417085C2 (en) | Eslicarbazepine acetate and methods for applying thereof | |
Massie et al. | Antihypertensive effects of mibefradil: A double‐blind comparison with diltiazem CD | |
CN105193822A (en) | Eslicarbazepine acetate and application method thereof | |
Zhou et al. | Pharmacokinetics, Safety and Tolerability of Tylerdipine Hydrochloride, a Novel Dihydropyridine Dual L/T-type Calcium Channel Blocker, after Single and Multiple Oral Doses in Healthy Chinese Subjects | |
Pierce | A review of the clinical pharmacokinetics and metabolism of the α1-adrenoceptor antagonist indoramin | |
Dienel et al. | Influence of losigamone on the pharmacokinetics of a combined oral contraceptive in healthy female volunteers | |
Fontes-Ribeiro et al. | Eslicarbazepine Acetate (BIA 2-093). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2607427 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/013882 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005331690 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005331690 Country of ref document: AU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05766682 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: PI0520258 Country of ref document: BR Kind code of ref document: A2 |